Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study
Joint Authors
Huang, Lvzhen
Li, Xiaoxin
Chen, Xiao-Li
Bai, Yu-Jing
Hu, Qin-Rui
Chen, Yi
Source
Issue
Vol. 2017, Issue 2017 (31 Dec. 2017), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2017-04-09
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
Objective.
To determine the prevalence and risk factors for the recurrence of retinopathy of prematurity (ROP) in Zone II Stage 3+ after ranibizumab treatment.
Methods.
This was a retrospective, nonrandomized, noncontrolled study that excluded Zone I and aggressive posterior ROP (APROP) cases.
Infants who developed Zone II Stage 3 ROP with plus disease and underwent initial intravitreal injection of ranibizumab (IVR) were recruited.
Patients were divided into 2 groups based on the outcome after initial ranibizumab treatment: recurrence of ROP or favorable outcome.
Data was collected and analyzed by SPSS 16.0.
Results.
Forty-two patients were included, and 80 eyes with Zone II Stage 3+ were subjected to IVR treatment.
Eleven of 42 patients (26.2%, 18 eyes) had a recurrence of ROP after the initial treatment.
On univariate analysis, preretinal hemorrhage before treatment was significantly different between the two groups (P=0.000).
Multivariate analysis found that preretinal hemorrhage before treatment was the only factor associated with the recurrence of ROP in our study (P=0.004).
Conclusions.
The recurrence rate of ROP in Zone II Stage 3+ after initial ranibizumab treatment was notable and preretinal hemorrhage before treatment was associated with the recurrence of ROP in our study.
American Psychological Association (APA)
Hu, Qin-Rui& Bai, Yu-Jing& Chen, Xiao-Li& Huang, Lvzhen& Chen, Yi& Li, Xiaoxin. 2017. Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study. Journal of Ophthalmology،Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1185012
Modern Language Association (MLA)
Hu, Qin-Rui…[et al.]. Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study. Journal of Ophthalmology No. 2017 (2017), pp.1-5.
https://search.emarefa.net/detail/BIM-1185012
American Medical Association (AMA)
Hu, Qin-Rui& Bai, Yu-Jing& Chen, Xiao-Li& Huang, Lvzhen& Chen, Yi& Li, Xiaoxin. Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study. Journal of Ophthalmology. 2017. Vol. 2017, no. 2017, pp.1-5.
https://search.emarefa.net/detail/BIM-1185012
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1185012